The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers-Reference-Cited by-同舟云学术

The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers

Published:2018-07-11 Issue:1 Volume:20 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Barrett Michael T.^ORCID,Lenkiewicz Elizabeth,Malasi Smriti,Basu Anamika,Yearley Jennifer Holmes,Annamalai Lakshmanan,McCullough Ann E.,Kosiorek Heidi E.,Narang Pooja,Wilson Sayres Melissa A.,Chen Meixuan,Anderson Karen S.,Pockaj Barbara A.

Funder

Desert Mountain Member’s C.A.R.E. (Cancer Awareness through Research and Education), Carefree AZ.

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-018-1004-0.pdf

Reference54 articles.

1. Taube JM, Anders RA, Young GD, Xu H, Sharma R, TL MM, Chen S, Klein AP, Pardoll DM, Topalian SL, Chen L. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.

2. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.

3. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, JA MK, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6(2):202–16.

4. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25(10):1935–40.

5. Le DT UJN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Application of Pembrolizumab in the Treatment of Triple Negative Breast Cancer;Advances in Clinical Medicine;2024

2. Prognostic significance and immunological role of HPRT1 in human cancers;Biomolecules and Biomedicine;2023-12-14

3. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer;Breast Cancer Research;2023-11-03

4. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial;Nature Communications;2023-10-20

5. Comparison of immunotherapy with chemotherapy on triple-negative breast cancer;International Conference on Modern Medicine and Global Health (ICMMGH 2023);2023-09-07